Mubadala Expands in Asia with Acquisition of UCB’s Mature Business in China

Strategic Investment Targets Growth in China’s Healthcare Market

Mubadala Investment Company, in collaboration with CBC Group, has acquired full ownership of UCB Pharma’s mature business in China. This acquisition, which includes UCB’s neurology and allergy portfolios, aligns with Mubadala’s strategic vision to expand its presence in Asia, focusing on high-growth sectors like healthcare. With the deal set to close in Q4 2024, this move marks a significant step in Mubadala’s commitment to enhancing healthcare access and addressing unmet needs in China’s growing CNS market.